Key facts
- It has raised $500K; the latest was Angel (individual) in Aug 2025.
- Notable investors include Y Combinator, Bullock Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Biocartesian
- ·The full record, as it builds
Funding rounds
No funding rounds for Biocartesian are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biocartesian
Developer of molecular imaging technology designed to accelerate biological data collection through chemistry-integrated microscopy. The company specializes in tissue profiling, throughput RNA (Ribonucleic Acid) and protein mapping, and AI-powered segmentation tools, enabling researchers to visualize molecular landscapes, reduce analysis time, and expand access to scalable, interpretable biological datasets.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Employees
- 3
- Website
- biocartesian.com/
- Ownership
- Privately Held (backing)
Biocartesian doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biocartesian shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biocartesian in its N-PORT filings yet. We sweep new filings monthly.